An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002
Phase of Trial: Phase I/II
Latest Information Update: 02 Sep 2017
At a glance
- Drugs Sapanisertib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Jul 2016 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 21 Jul 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 21 Jul 2016 Status changed from not yet recruiting to recruiting.